In 2018, Verve was founded by cardiology, gene editing and drug development pioneers seeking to find a solution for the global epidemic that is cardiovascular disease (CVD). Despite improvements to treatment and care over the last several decades, CVD remains the leading cause of death worldwide.
Disrupting the Chronic Care Model for Treating ASCVD
At Verve, we are striving to build the preeminent company developing gene editing medicines to treat atherosclerotic cardiovascular disease (ASCVD). We are leveraging the expertise and capabilities of our team whose singular focus is on addressing the root causes of this condition that touches so many individuals worldwide, whether personally or through a loved one. Our goal is to disrupt the chronic care model for treating ASCVD by providing a new therapeutic approach with single-course gene editing medicines.
Creating the Future of Medicine
We are working hard to achieve this, and our work is delivering results. Within five years of Verve’s inception, we have completed preclinical testing of our lead program, VERVE-101, initiated the first in-human clinical trial for a gene editing medicine for heterozygous familial hypercholesterolemia, a form of ASCVD, and announced interim data from our heart-1 clinical trial.
Bringing together our team of experts and leveraging multiple breakthroughs in 21st century biomedicine, we are well positioned to realize a new future of longevity and vitality for hundreds of millions of people around the globe with or at risk for ASCVD.